Amphastar enters $2.8M R&D agreement with related-party Hanxin for AMP-107 cell banks

Amphastar Pharmaceuticals, Inc.

Agreement with Nanjing Hanxin to develop Recombinant Peptide Research Cell Banks (RCBs) for product candidate AMP-107.
Total cost not to exceed ~$2.8M; initial payment ~$0.3M; payments in Chinese yuan.
Hanxin majority-owned by CEO Jack Zhang, Chairman Mary Luo, and family; approved by independent audit committee.
Term of three years; all title to RCBs and related IP will belong to Amphastar.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.